Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 QTc and Safety with Pertuzumab in HER2+ MBC
NCT00943670Phase 2Completed
- Sponsor
- Genentech
- Start
- Jul 2009
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in breast cancer, sponsored by Genentech. Primary endpoint: Change From Baseline in Mean Duration of the QTc Interval. Started Jul 2009; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00943670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943670.